BRPI0917262A2 - composto, composiçáo, método de tratamento ou prevenção de doença cardiovascular, método de fabricação de 3,4-metilenedioxifenil lipoato (inv-7065), método para tratamento de um indivíduo, suplemento dentário, composição anti-inflamatória, composição farmacêutica para tratamento de formação de placas aórticas humanas em um indivíduo, método para redução de formação de placas em um indivíduo, uso de um composto. - Google Patents
composto, composiçáo, método de tratamento ou prevenção de doença cardiovascular, método de fabricação de 3,4-metilenedioxifenil lipoato (inv-7065), método para tratamento de um indivíduo, suplemento dentário, composição anti-inflamatória, composição farmacêutica para tratamento de formação de placas aórticas humanas em um indivíduo, método para redução de formação de placas em um indivíduo, uso de um composto.Info
- Publication number
- BRPI0917262A2 BRPI0917262A2 BRPI0917262A BRPI0917262A BRPI0917262A2 BR PI0917262 A2 BRPI0917262 A2 BR PI0917262A2 BR PI0917262 A BRPI0917262 A BR PI0917262A BR PI0917262 A BRPI0917262 A BR PI0917262A BR PI0917262 A2 BRPI0917262 A2 BR PI0917262A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- composition
- treating
- compound
- formation
- Prior art date
Links
- 238000000034 method Methods 0.000 title 3
- 150000001875 compounds Chemical class 0.000 title 2
- 239000000203 mixture Substances 0.000 title 2
- -1 3,4-methylenedioxyphenyl lipoate Chemical compound 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000000598 lipoate effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000007505 plaque formation Effects 0.000 title 1
- 239000013589 supplement Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8642508P | 2008-08-05 | 2008-08-05 | |
| PCT/US2009/052893 WO2010017323A1 (en) | 2008-08-05 | 2009-08-05 | Novel methylenedioxy phenolic compounds and their use to treat disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0917262A2 true BRPI0917262A2 (pt) | 2015-11-10 |
Family
ID=41172398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917262A BRPI0917262A2 (pt) | 2008-08-05 | 2009-08-05 | composto, composiçáo, método de tratamento ou prevenção de doença cardiovascular, método de fabricação de 3,4-metilenedioxifenil lipoato (inv-7065), método para tratamento de um indivíduo, suplemento dentário, composição anti-inflamatória, composição farmacêutica para tratamento de formação de placas aórticas humanas em um indivíduo, método para redução de formação de placas em um indivíduo, uso de um composto. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8198317B2 (enExample) |
| EP (1) | EP2324005A1 (enExample) |
| JP (1) | JP2011530525A (enExample) |
| KR (1) | KR20110042108A (enExample) |
| CN (1) | CN102149702A (enExample) |
| AU (1) | AU2009279667A1 (enExample) |
| BR (1) | BRPI0917262A2 (enExample) |
| CA (1) | CA2733430A1 (enExample) |
| IL (1) | IL211076A0 (enExample) |
| RU (1) | RU2011108587A (enExample) |
| WO (1) | WO2010017323A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1007600A2 (pt) * | 2009-04-23 | 2019-09-24 | Invasc Therapeutics Inc | composições e métodos para tratamento de doenças cardiovasculares |
| CN106957298B (zh) * | 2017-04-18 | 2019-07-16 | 湖南中医药大学 | 一种硫辛酸苯酚酯衍生物及其制备方法和应用 |
| CN110305102B (zh) * | 2019-08-13 | 2020-11-24 | 陕西中医药大学 | 1,3-苯并二噁茂天然多酚酸酯类化合物及其降血脂应用 |
| CN112745291A (zh) * | 2019-10-29 | 2021-05-04 | 浙江大学宁波理工学院 | 一种具有HMG-CoA还原酶抑制活性的化合物、药物组合物及应用 |
| US11306076B2 (en) * | 2020-05-11 | 2022-04-19 | Xi'an Taikomed Pharmaceutical Technology Co., Ltd. | Silibinin lipoic acid ester with hepatoprotective activity and a method of preparing the same |
| CN115047092B (zh) * | 2022-04-07 | 2023-10-20 | 济宁医学院 | 一种血管紧张素转移酶ii抑制剂的筛选方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031275A1 (en) * | 1998-02-09 | 2001-10-18 | Forse R Armour | Sesamol inhibitor of delta-5-desaturase activity and uses therefor |
| EP1229034B1 (en) * | 2001-01-31 | 2005-04-13 | Pfizer Products Inc. | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes |
| KR20030070150A (ko) * | 2001-01-31 | 2003-08-27 | 화이자 프로덕츠 인크. | Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체 |
-
2009
- 2009-08-05 CN CN2009801354528A patent/CN102149702A/zh active Pending
- 2009-08-05 US US12/536,295 patent/US8198317B2/en not_active Expired - Fee Related
- 2009-08-05 KR KR1020117005383A patent/KR20110042108A/ko not_active Withdrawn
- 2009-08-05 EP EP09791197A patent/EP2324005A1/en not_active Withdrawn
- 2009-08-05 BR BRPI0917262A patent/BRPI0917262A2/pt not_active Application Discontinuation
- 2009-08-05 AU AU2009279667A patent/AU2009279667A1/en not_active Abandoned
- 2009-08-05 RU RU2011108587/04A patent/RU2011108587A/ru not_active Application Discontinuation
- 2009-08-05 JP JP2011522226A patent/JP2011530525A/ja not_active Withdrawn
- 2009-08-05 CA CA2733430A patent/CA2733430A1/en not_active Abandoned
- 2009-08-05 WO PCT/US2009/052893 patent/WO2010017323A1/en not_active Ceased
-
2011
- 2011-02-03 IL IL211076A patent/IL211076A0/en unknown
-
2012
- 2012-06-12 US US13/494,606 patent/US20130157986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130157986A1 (en) | 2013-06-20 |
| EP2324005A1 (en) | 2011-05-25 |
| CN102149702A (zh) | 2011-08-10 |
| JP2011530525A (ja) | 2011-12-22 |
| IL211076A0 (en) | 2011-04-28 |
| US8198317B2 (en) | 2012-06-12 |
| WO2010017323A1 (en) | 2010-02-11 |
| US20100035849A1 (en) | 2010-02-11 |
| CA2733430A1 (en) | 2010-02-11 |
| AU2009279667A1 (en) | 2010-02-11 |
| KR20110042108A (ko) | 2011-04-22 |
| RU2011108587A (ru) | 2012-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0905733A2 (pt) | "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica" | |
| BRPI0913293A2 (pt) | método para inibir a formação de uma biopelícula, composição farmacêutica tópica, rinsagem cirúrgica, bandagem, composição de limpeza, e, rinsagem dental. | |
| WO2006078463A3 (en) | Method for treating cardiovascular disease | |
| BRPI0821860A2 (pt) | Composição para cuidado oral, método, uso de um aminoácido básico, e, método para tratar dentes sensíveis dentro de uma cavidade oral | |
| EA201100969A1 (ru) | Солевые формы органического соединения | |
| BRPI0924734A2 (pt) | composição oral, e, métodos para preparar a composição oral, para alvejar um ingrediente ativo, para depositar um material bacteriostático ou bactericida sobre superfícies orais, para retardar ou previnir cárie dentária, método para ocluir túbulos dentinais, para tratar uma lesão por cárie, para calcificar uma polpa de dente exposta, e para calcificar a base de ou a totalidade de um buraco ou de uma fissura em um dente. | |
| BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
| ZA200810756B (en) | Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation | |
| HUE045784T2 (hu) | Eliglusztát (Genz 112638) mint glükozilceramid-szintáz inhibitor Fabry- vagy Gaucher-kór kezelési eljárásában történõ alkalmazásra, az eljárás tartalmazza az egyedi terápiás dózisnak a beteg P-450 metabolizmusához történõ beállítását | |
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| BRPI0811816A2 (pt) | "forma de dosagem de picoplatina estabilizada, método para preparar uma forma de dosagem de picoplatina estabilizada, composições, kit, pluralidade de kits, método para tratamento de câncer e uso de uma quantidade eficaz da forma de dosagem" | |
| EP1905459B8 (en) | Method of producing tooth, set of teeth, and method of producing tissue | |
| BRPI0905687A2 (pt) | "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto" | |
| BRPI0518776A2 (pt) | composiÇço e mÉtodo para o cuidado oral, e, mÉtodos para inibir a inflamaÇço em um tecido oral de um paciente, e para promover a saéde oral em um paciente | |
| CY2018006I1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
| WO2010044585A3 (en) | Piperidine compounds, pharmaceutical composition comprising the same and its use | |
| WO2009099553A3 (en) | Use of kinase inhibitor in treatment of atherosclerosis | |
| BRPI0922870A2 (pt) | uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético | |
| BRPI0906687A2 (pt) | Composição para cuidado oral, e, método para combater a hipersensibilidade da dentina | |
| WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
| BRPI0919694A2 (pt) | composto, composto farmacêutica, uso de um composto, e, método de tratamento de uma doença. | |
| WO2006055352A3 (en) | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally | |
| EP2114418A4 (en) | ORAL DOSAGE FORM WITH STABILIZED PICOPLATIN | |
| ECSP10010464A (es) | Uso de ranolazina para el tratamiento de enfermedades cardiovasculares | |
| UA90893C2 (ru) | Пероральная дозированная форма производных гемцитабина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |